Eagle Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $20.1M | Sell |
207,698
-62,272
| -23% | -$4.75M | 0.1% | 190 |
|
|
2024
Q2 | $18.5M | Buy |
269,970
+1
| +0% | +$67 | 0.1% | 193 |
|
|
2024
Q1 | $19.7M | Sell |
269,969
-47,570
| -15% | -$3.66M | 0.1% | 195 |
|
|
2023
Q4 | $25.7M | Buy |
317,539
+60,697
| +24% | +$4.72M | 0.14% | 161 |
|
|
2023
Q3 | $19.2M | Buy |
256,842
+511
| +0.2% | +$39.3K | 0.11% | 185 |
|
|
2023
Q2 | $19.8M | Buy |
256,331
+3,130
| +1% | +$250K | 0.11% | 184 |
|
|
2023
Q1 | $21M | Sell |
253,201
-218
| -0.1% | -$18.1K | 0.12% | 160 |
|
|
2022
Q4 | $21.6M | Buy |
253,419
+44,984
| +22% | +$3.56M | 0.13% | 164 |
|
|
2022
Q3 | $12.9M | Buy |
208,435
+28,303
| +16% | +$1.78M | 0.08% | 206 |
|
|
2022
Q2 | $11.1M | Buy |
180,132
+36,472
| +25% | +$2.26M | 0.07% | 233 |
|
|
2022
Q1 | $8.54M | Sell |
143,660
-629
| -0.4% | -$40.2K | 0.04% | 300 |
|
|
2021
Q4 | $10.6M | Buy |
144,289
+210
| +0.1% | +$14.5K | 0.05% | 301 |
|
|
2021
Q3 | $10.1M | Buy |
144,079
+15,857
| +12% | +$1.11M | 0.05% | 316 |
|
|
2021
Q2 | $8.83M | Buy |
128,222
+66,257
| +107% | +$4.42M | 0.04% | 348 |
|
|
2021
Q1 | $4.12M | Buy |
+61,965
| New | +$4M | 0.02% | 424 |
|
|
2020
Q2 | – | Sell |
-27,068
| Closed | -$2.02M | – | 585 |
|
|
2020
Q1 | $2.02M | Buy |
27,068
+14,585
| +117% | +$1.01M | 0.01% | 468 |
|
|
2019
Q4 | $811K | Sell |
12,483
-427
| -3% | -$27.8K | ﹤0.01% | 574 |
|
|
2019
Q3 | $818K | Sell |
12,910
-232
| -2% | -$15.2K | ﹤0.01% | 561 |
|
|
2019
Q2 | $887K | Buy |
13,142
+16
| +0.1% | +$1.05K | ﹤0.01% | 558 |
|
|
2019
Q1 | $853K | Buy |
13,126
+433
| +3% | +$28.8K | ﹤0.01% | 547 |
|
|
2018
Q4 | $793K | Sell |
12,693
-1,073
| -8% | -$75K | 0.01% | 539 |
|
|
2018
Q3 | $1.06M | Sell |
13,766
-47
| -0.3% | -$3.55K | 0.01% | 552 |
|
|
2018
Q2 | $978K | Buy |
13,813
+32
| +0.2% | +$2.26K | 0.01% | 556 |
|
|
2018
Q1 | $1.04M | Buy |
13,781
+43
| +0.3% | +$3.42K | 0.01% | 562 |
|
|
2017
Q4 | $1.09M | Sell |
13,738
-23,756
| -63% | -$1.8M | 0.01% | 566 |
|
|
2017
Q3 | $3.13M | Buy |
37,494
+11,103
| +42% | +$849K | 0.02% | 490 |
|
|
2017
Q2 | $1.87M | Buy |
26,391
+65
| +0.2% | +$4.33K | 0.01% | 554 |
|
|
2017
Q1 | $1.79M | Sell |
26,326
-20,278
| -44% | -$1.43M | 0.01% | 571 |
|
|
2016
Q4 | $3.34M | Sell |
46,604
-21,051
| -31% | -$1.56M | 0.02% | 478 |
|
|
2016
Q3 | $5.35M | Sell |
67,655
-979
| -1% | -$79.5K | 0.04% | 403 |
|
|
2016
Q2 | $5.72M | Sell |
68,634
-1,056
| -2% | -$93.7K | 0.04% | 395 |
|
|
2016
Q1 | $6.4M | Buy |
69,690
+592
| +0.9% | +$53.4K | 0.04% | 377 |
|
|
2015
Q4 | $6.99M | Sell |
69,098
-578
| -0.8% | -$60.1K | 0.05% | 369 |
|
|
2015
Q3 | $6.84M | Sell |
69,676
-6,360
| -8% | -$706K | 0.05% | 375 |
|
|
2015
Q2 | $8.9M | Sell |
76,036
-1,079
| -1% | -$118K | 0.05% | 346 |
|
|
2015
Q1 | $7.57M | Sell |
77,115
-1,191
| -2% | -$121K | 0.04% | 370 |
|
|
2014
Q4 | $7.38M | Buy |
78,306
+22,575
| +41% | +$2.33M | 0.04% | 374 |
|
|
2014
Q3 | $5.93M | Sell |
55,731
-3,202
| -5% | -$314K | 0.03% | 403 |
|
|
2014
Q2 | $4.89M | Sell |
58,933
-989
| -2% | -$77K | 0.03% | 458 |
|
|
2014
Q1 | $4.25M | Sell |
59,922
-531
| -0.9% | -$41.6K | 0.02% | 499 |
|
|
2013
Q4 | $4.54M | Sell |
60,453
-62,895
| -51% | -$4.38M | 0.03% | 453 |
|
|
2013
Q3 | $7.84M | Buy |
123,348
+60,088
| +95% | +$3.59M | 0.04% | 408 |
|
|
2013
Q2 | $3.24M | Buy |
+63,260
| New | +$3.3M | 0.02% | 533 |
|
Other funds holding GILD
Eagle Asset Management's GILD Position: Q3 2024 in Review
Eagle Asset Management reduced its Gilead Sciences (GILD) stake by 23% in Q3 2024, selling an estimated $4.75M and leaving 207,698 shares worth $20.1M. The position accounts for 0.1% of the portfolio, ranked #190.
Eagle Asset Management first reported a position in GILD in Q2 2013 and has held it in 43 quarters since. The position peaked at $25.7M in Q4 2023. 1,718 funds tracked by Wall St. Rank hold GILD as of Q3 2024.
- Eagle Asset Management held 207,698 shares of Gilead Sciences worth $20.1M as of Q3 2024.
- Eagle Asset Management sold 62,272 Gilead Sciences shares in Q3 2024, an estimated $4.75M.
- Gilead Sciences made up 0.1% of Eagle Asset Management's portfolio in Q3 2024, its #190 holding.
- Eagle Asset Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 43 quarters since.
- Eagle Asset Management's Gilead Sciences position peaked at $25.7M in Q4 2023.
- 1,718 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.
Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.